Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

被引:0
|
作者
Shaffer, Brian C. [1 ]
Gooptu, Mahasweta [2 ]
Defor, Todd E. [3 ]
Maiers, Martin [3 ]
Bolanos-Meade, Javier [4 ]
Abboud, Ramzi [5 ]
Briggs, Adrienne D. [6 ]
Khimani, Farhad [7 ]
Modi, Dipenkumar [8 ]
Newcomb, Richard [9 ]
Shpall, Elizabeth J. [10 ]
Bupp, Caitrin [3 ]
Spellman, Stephen R. [3 ]
Stefanski, Heather E. [3 ]
Shaw, Bronwen E. [11 ]
Auletta, Jeffery J. [3 ,12 ]
Devine, Steven M. [3 ]
Jimenez, Antonio M. Jimenez [13 ]
Al Malki, Monzr M. [14 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY USA
[2] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA USA
[3] NMDP, Ctr Int Blood & Marrow Transplant Res, CIBMTR, Minneapolis, MN 55401 USA
[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] HonorHlth, Canc Transplant Inst, Scottsdale, AZ USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immuno, Tampa, FL USA
[8] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA
[11] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, CIBMTR, Milwaukee, WI USA
[12] Nationwide Childrens Hosp, Hematol Oncol BMT & Infect Dis, Columbus, OH USA
[13] Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[14] City Hope Natl Med Ctr, Duarte, CA USA
关键词
HEMATOPOIETIC-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; PHASE-II TRIAL; HEMATOLOGIC MALIGNANCIES; HLA; BLOOD; INDEX; PREVENTION; ABATACEPT; GVHD;
D O I
10.1200/JCO.24.00184
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)-based prophylaxis. Methods Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. Results Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syndromes (29.2%). Median patient age was 60.7 years (range, 18.0-82.7) and median follow-up was 36.6 (range, 3.0-77.8) months. When compared with MUD HCT with PTCy, MMUD HCT with PTCy had similar OS (hazard ratio [HR], 0.96 [95% CI, 0.823 to 1.11]; P = .60) and GRFS (HR, 0.90 [0.79 to 1.02]; P = .1). When compared with MUD HCT with CNI, OS was improved after MUD HCT with PTCy (HR, 0.88 [0.80 to 0.96]; P = .004) and GRFS was improved with PTCy after either MUD (HR, 0.61 [0.57 to 0.66]; P < .0001) or MMUD (HR, 0.68 [0.60 to 0.76]; P < .0001) HCT. Benefit from PTCy was independent of patient ancestry. Global registry level analysis demonstrated that inclusion of MMUD increased donor availability regardless of recipient ancestry. Conclusion Use of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Low-dose antithymocyte globulin, post-transplant cyclophosphamide and sirolimus as graft-versus-host disease prophylaxis in unrelated donor transplants
    Greco, R.
    Crucitti, L.
    Vago, L.
    Cieri, N.
    Giglio, F.
    Stanghellini, M. T. Lupo
    Morelli, M.
    Barbanti, M. C.
    Piemontese, S.
    Perini, T.
    Sala, E.
    Pavesi, F.
    Messina, C.
    Milani, R.
    Marcatti, M.
    Marktel, S.
    Carrabba, M.
    Bernardi, M.
    Corti, C.
    Assanelli, A.
    Bonini, C.
    Ciceri, F.
    Peccatori, J.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S438 - S439
  • [22] Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
    Ardizzoia, Federica
    Lorentino, Francesca
    Bruno, Alessandro
    Marktel, Sarah
    Giglio, Fabio
    Clerici, Daniela
    Farina, Francesca
    Mastaglio, Sara
    Piemontese, Simona
    Assanelli, Andrea A.
    Carrabba, Matteo G.
    Bernardi, Massimo
    Corti, Consuelo
    Peccatori, Jacopo
    Ciceri, Fabio
    Greco, Raffaella
    Lupo-Stanghellini, Maria Teresa
    [J]. HAEMATOLOGICA, 2022, 107 (11) : 2748 - 2751
  • [23] Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
    Ardizzoia, Federica
    Lorentino, Francesca
    Bruno, Alessandro
    Marktel, Sarah
    Giglio, Fabio
    Clerici, Daniela
    Farina, Francesca
    Mastaglio, Sara
    Piemontese, Simona
    Assanelli, Andrea A.
    Carrabba, Matteo G.
    Bernardi, Massimo
    Corti, Consuelo
    Peccatori, Jacopo
    Ciceri, Fabio
    Greco, Raffaella
    Lupo-Stanghellini, Maria Teresa
    [J]. HAEMATOLOGICA, 2022, 107 : 2748 - 2751
  • [24] Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations
    Kunacheewa, Chutima
    Owattanapanish, Weerapat
    Jirabanditsakul, Chutirat
    Issaragrisil, Surapol
    [J]. CELL TRANSPLANTATION, 2020, 29
  • [25] Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation
    Mehta, Rohtesh S.
    Saliba, Rima M.
    Chen, Julianne
    Rondon, Gabriela
    Hammerstrom, Aimee E.
    Alousi, Amin
    Qazilbash, Muzaffar
    Bashir, Qaiser
    Ahmed, Sairah
    Popat, Uday
    Hosing, Chitra
    Khouri, Issa
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Ciurea, Stefan O.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (03) : 444 - 455
  • [26] Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease
    Al-Homsi, Ahmad Samer
    Roy, Tara S.
    Cole, Kelli
    Feng, Yuxin
    Duffner, Ulrich
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (04) : 604 - 611
  • [27] Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes
    Herzog, Shannon
    Shanley, Ryan
    Holtan, Shernan G.
    MacMillan, Margaret L.
    Weisdorf, Daniel J.
    El Jurdi, Najla
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (07):
  • [28] Incidence of chronic graft versus host disease using post-transplant cyclophosphamide in HLA-matched versus haploidentical donors.
    Hitt, Mary Moses
    Yimer, Wondwosen
    Milner, Carter Payne
    Herrin, Vincent E.
    Elkins, Stephanie
    Bigelow, Carolyn L.
    Hilal, Talal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in HLA matched sibling donor stem cell transplantation for patients with acute leukemia.
    Elshamy, Alaa Nabil
    Abdelmohsen, Essam Ali
    Denewer, Mai
    Mabed, Mohamed Nasr
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Comparison of pre-transplant thymoglobulin and post-transplant prednisolone as graft-versus-host disease prophylaxis in matched unrelated donor, peripheral blood stem cell transplantation
    Ritchie, D. S.
    Lim, A.
    Li, E.
    Mason, K.
    Hoyt, R.
    He, S.
    Bajel, A.
    Roberts, A. W.
    Grigg, A. P.
    Szer, J.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 : S152 - S152